Results 221 to 230 of about 10,059 (251)
Some of the next articles are maybe not open access.
Anidulafungin: an echinocandin antifungal
Expert Opinion on Investigational Drugs, 2004Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
openaire +2 more sources
Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin
The Journal of Clinical Pharmacology, 2005There is considerable interest in combining echinocandin and triazole antifungal agents for treatment of invasive fungal infections; however, information is needed regarding the tolerability and potential for pharmacokinetic interactions. Anidulafungin is a semisynthetic echinocandin, and voriconazole is an extended‐spectrum triazole.
Alice Baruch +3 more
openaire +2 more sources
Anidulafungin: when and how? The clinician’s view
Mycoses, 2011SummaryAnidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage ...
Jomy M. George, Annette C. Reboli
openaire +2 more sources
Anidulafungin: a drug evaluation of a new echinocandin
Expert Opinion on Pharmacotherapy, 2008Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium.The intention of this review is to provide a drug evaluation of anidulafungin, including its spectrum of activity ...
Jomy M Joseph +2 more
openaire +3 more sources
Pharmacological Properties of Antifungal Drugs with a Focus on Anidulafungin
Drugs, 2009Drug classes for the treatment of invasive fungal infections include the polyenes, the triazoles and the echinocandins. Older agents such as the commonly used amphotericin B have a number of limitations, including toxicity and requirements for monitoring during treatment.
MAZZEI, TERESITA, NOVELLI, ANDREA
openaire +4 more sources
Tissue Distribution of Anidulafungin in Neonatal Rats
Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2012Anidulafungin, an echinocandin, is currently approved for treatment of fungal infections in adults. There is a high unmet medical need for treatment of fungal infections in neonatal patients, who may be at higher risk of infections involving bone, brain, and heart tissues. This in vivo preclinical study investigated anidulafungin distribution in plasma,
Jian Lin +10 more
openaire +3 more sources
Anidulafungin: A new echinocandin with a novel profile
Clinical Therapeutics, 2005Until recently, available treatment for serious fungal infections comprised amphotericin B and azoles, which have limitations. Renal toxicity is a major concern with amphotericin B, while drug-drug interactions, hepatotoxicity, and skin rashes are the primary concerns with the azole medications.
openaire +3 more sources
Anidulafungin, a new antifungal drug
Antibiotiques, 2007Resume Objectifs L’essor de nouvelles molecules d’antifongiques est lie au developpement des candidoses invasives ainsi qu’a l’apparition de resistances aux molecules plus anciennes. Methodes La recherche au sein de l’Industrie Pharmaceutique et au moyen de la consultation des donnees publiees nous a permis de reconnaitre une nouvelle classe d ...
openaire +2 more sources
Anidulafungine : perspectives cliniques en 2007
Réanimation, 2007Resume Les candidoses invasives representent une complication nosocomiale grave et redoutee, tout particulierement dans les services de reanimation. La mise a disposition recente de nouveaux antifongiques pour les cliniciens est un des reflets du poids croissant des pathologies invasives liees a des micro-organismes fongiques a l’hopital au cours de ...
Olivier Lortholary, Olivier Lortholary
openaire +2 more sources